硅谷银行：2017年上半年全球医疗健康行业投资与退出趋势报告（英文版）（27页）.pdf

1、Trends in Healthcare Investments and Exits Innovations Spur Healthcare Investment and Fundraising Paul Schuber Senior Associate SVB Analytics Written by: Jonathan Norris Managing Director Silicon Valley Bank Caitlin Tolman Senior Associate Silicon Valley Bank Visit  Follow SVB_Financial Engage

2、#SVBHealthcare Mid-Year 2017  Table of Contents Trends in Healthcare Investments and Exits MidTrends in Healthcare Investments and Exits Mid- -Year 2017Year 20172 2 Mid-Year 2017 Key Highlights3 Healthcare Investments and Fundraising4 Healthcare Big Exit M these returns now are approaching what

3、 we see from biopharma M if that holds through year-end, this would be a record. Device also appears likely to match 2016 in deals and dollars. Cardiovascular declined significantly in 1H 2017. Dx/Tools Series A has been strong through 1H 2017. Almost 40% of the deals did not disclose investors, whi

4、ch suggests significant angel investment. Median deal value for Dx/Tools is about $6M, double the device median but behind biopharma at $9M. 58 31 # of Deals 51 30 # of Deals Trends in Healthcare Investments and Exits MidTrends in Healthcare Investments and Exits Mid- -Year 2017Year 2017 U.S. Compan

5、y Formation: Deals and Investments in Series A 126 64 20162017 # of Deals  Immuno-oncology Dominates Biopharma Series A 2016  1H 2017 Series A Oncology Financings Amazingly, since 2016, $1.3B has been invested in Immuno-oncology. This represents about a third of all biopharma Series A inve

6、stment but only 18% of total deals. The median deal size of $30M signals that larger VC syndicates of institutional investors are putting money in new Immuno-oncology startups. From a geographic perspective, Massachusetts had the most deals with 10, followed by Northern California (8) and Southern C